Articles tagged "Antibodies"

2019 American Transplant Congress
Natural Antibodies and Left Ventricular Assist Device Complications
S. B. See¹, A. Pinsino², R. Shihab¹, N. Kunimune¹, D. Onat², E. Hittesdorf³, A. R. Garan², V. K. Topkara², Y. Naka⁴, H. Takayama⁴, K. Takeda⁴, P. Colombo², M. Yuzefpolskaya², G. Wagener³, E. Zorn¹
¹Columbia Center for Translational Immunology, Columbia University, New York, NY, ²Division of Cardiology, Columbia University, New York, NY, ³Department of Anesthesiology, Columbia University, New York, NY, ⁴Department of Surgery, Columbia University, New York, NY
*Purpose: Left ventricular assist devices (LVAD) are used as a bridge to heart transplantation or destination therapy for advanced heart failure. For all its benefits,…
2019 American Transplant Congress
5-Year Post-Transplant Outcomes with Bortezomib-Based Desensitization in Renal Transplant Recipients
K. Zheng¹, S. Tremblay¹, A. R. Shields², M. A. Cardi², J. Kremer², R. R. Alloway¹, E. S. Woodle¹
¹U of Cincinnati, Cincinnati, OH, ²Christ Hospital, Cincinnati, OH
*Purpose: Renal transplant (RT) after desensitization (DS) has been associated with increased rejection rates. Proteasome inhibitor(PI)-based DS yields significant reductions in HLA Ab among sensitized…
2019 American Transplant Congress
Post-Transplant Anti- A Titer >1:128 in A2-Incompatible Kidney Recipients is Associated with Subclinical Antibody Mediated Rejection
V. Kumar, D. Williams, P. MacLennan, M. Mustian, B. Orandi, L. Williams, J. Locke
University of Alabama at Birmingham, Birmingham, AL
*Purpose: Decreased antigen expression among blood group A, subtype 2 (A2), donor kidneys allows these kidneys to be considered as universal donor kidneys and under…
2018 American Transplant Congress
Genetically Modified Porcine Erythrocytes: A Cell Model for Studying Human Preformed Antibody-Dependent Xenoimmune Responses In Vitro
Z. Wang, G. Martens, J. Ladowski, M. Tector, A. Tector.
Surgery, University of Alabama at Birmingham, Birmingham, AL.
Background: Powerful gene editing technology is a promising approach to provide genetically-modified pigs as donors for clinical cell, tissue and organ xenotransplantation. Prior to starting…
2018 American Transplant Congress
A Follow-Up Report on the Use of IVIG+Rituximab to Reduce Donor Specific Antibodies and Improve Transplant Rates in Highly-Sensitized Patients Awaiting Deceased Donor Kidney Transplantation
R. Najjar, E. Huang, A. Vo, J. Choi, K. Lim, S. Louie, A. Peng, S. Sethi, M. Toyoda, X. Zhang, S. Jordan.
Medicine/Nephrology, Cedars Sinai Medical Center, Los Angeles, CA.
Introduction: Desensitization (DES) with IVIG/rituximab is associated with a reduction in donor specific antibodies (DSA), improved transplant rates and outcomes in highly-sensitized (HS) patients. We…
2018 American Transplant Congress
Clinical Response to Salvage Bortezomib Therapy for Antibody Mediated Rejection and Mixed Acute Rejection in a High Immunologic Risk Renal Transplant Population
A. Lichvar, J. Benken, E. Benedetti.
University of Illinois at Chicago, Chicago, IL.
Background: Proteasome inhibitor (PI) containing regimens treat antibody mediated rejection (AMR) and mixed acute rejection (MAR) due to elimination of donor specific antibody (DSA). Commonly,…
2018 American Transplant Congress
Sharing Works; Avoiding Kidney Transplantation to an Unintended Recipient by Precision Virtual Cross Match with Excellent Outcomes
G. Roll,¹ A. Webber,¹ M. Travakol,¹ D. Gae,¹ L. Mayen,² V. Corpuz,¹ J. Roberts,¹ N. Ascher,¹ P. Stock,¹ R. Rajalingam.¹
¹UCSF, San Francisco; ²Donor Network West, San Ramon.
Aim: It was recently estimated that 19.2% of imported kidneys go into an unintended recipient(UR), most commonly due to a positive crossmatch(AJT 2017, 17:2139) so…
2018 American Transplant Congress
Evaluation of Hepatitis B Vaccination in Transplant Candidates
M. Bosaeed, Y. AlJishi, S. Husain, C. Rotstein, A. Humar, D. Kumar.
UHN, Toronto, Canada.
Background:Hepatitis B virus (HBV) vaccine series is recommended for all organ transplant candidates; high doses of vaccine are generally given to those with renal disease;…
2018 American Transplant Congress
Type I NKT Cells Augment Humoral and Cellular Alloimmunity in Response to Hepatocyte Transplantation
S. Elzein, J. Zimmerer, B. Ringwald, C. Avila, G. Bumgardner.
Surgery, The Ohio State University Wexner Medical Center, Columbus, OH.
Hepatocyte transplantation (HcTx) is a potential therapeutic modality for patients with liver disease. Despite examples of antigen acceptance in the liver, allogeneic HcTx into patients…
2018 American Transplant Congress
modified DFPP Can Eliminate Donor-Reactive IgG Antibody with Preserving Fibrinogen before Kidney Transplantation
D. Iwami,¹ T. Matsumoto,² K. Hotta,¹ M. Ota,² Y. Chiba,² H. Higuchi,¹ N. Shinohara.¹
¹Renal and Genitourinary Surgery, Hokkaido University, Graduate School of Medicine, Sapporo, Hokkaido, Japan; ²Medical Engineering Center, Hokkaido University Hospital, Sapporo, Hokkaido, Japan.
BACKGROUND: Elimination of preexisting IgG antibodies against donor antigen is an important role before antibody-incompatible (i.e. ABO-incompatible and donor-specific antibody positive) kidney transplantation. Plasma exchange…